Avizakimab, formerly known as BOS161721, represents a innovative medicinal approach to treating immune-mediated disorders. This biological substance selectively targets IL-18 , a vital cytokine implicated in https://woodykdvl053227.blog5.net/94986546/avizakimab-a-thorough-exploration-into-bos161721-s-capability